{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:20:08Z","timestamp":1760235608124,"version":"build-2065373602"},"reference-count":76,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.<\/jats:p>","DOI":"10.3390\/cancers13174479","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T10:59:12Z","timestamp":1630925952000},"page":"4479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0702-617X","authenticated-orcid":false,"given":"Sophie","family":"Beaumont","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"},{"name":"Melbourne Dental School, University of Melbourne, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon","family":"Harrison","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia"},{"name":"Centre of Excellence for Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"},{"name":"Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Er","sequence":"additional","affiliation":[{"name":"Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw\u20142014 Update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.4317\/medoral.24318","article-title":"A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy","volume":"26","author":"Fusco","year":"2021","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-160X-6-11","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients","volume":"6","author":"Walter","year":"2010","journal-title":"Head Face Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00520-016-3492-8","article-title":"Response to letter to the Editors\u2014Safety of long-term denosumab therapy","volume":"25","author":"Stopeck","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00223-017-0351-7","article-title":"New agents in the Treatment of Myeloma Bone Disease","volume":"102","author":"Ring","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40902-016-0099-4","article-title":"Medication-related osteonecrosis of the jaw: A preliminary retrospective study of 130 patients with multiple myeloma","volume":"39","author":"Choi","year":"2017","journal-title":"Maxillofac. Plast. Reconstr. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40729-021-00323-0","article-title":"Clinical considerations for medication-related osteonecrosis of the jaw: A comprehensive literature review","volume":"7","author":"Kawahara","year":"2021","journal-title":"Int. J. Implant. Dent."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.archoralbio.2018.09.016","article-title":"The rise and fall of the alveolar process: Dependency of teeth and metabolic aspects","volume":"96","author":"Jonasson","year":"2018","journal-title":"Arch. Oral Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/iai.64.7.2371-2380.1996","article-title":"Bacterially induced bone destruction: Mechanisms and misconceptions","volume":"64","author":"Nair","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00784-010-0507-6","article-title":"The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes\u2014in vitro study","volume":"16","author":"Pabst","year":"2012","journal-title":"Clin. Oral Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2014Characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00520-015-2908-1","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"Body","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5847429","DOI":"10.1155\/2020\/5847429","article-title":"Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and\/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study","volume":"2020","author":"Zhou","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/bcp.14681","article-title":"Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications","volume":"87","author":"Teoh","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Giudice, A., Antonelli, A., Chiarella, E., Baudi, F., Barni, T., and Di Vito, A. (2020). The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120423"},{"key":"ref_25","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic Acid-Related Angiogenesis Modifications and Survival in Advanced Breast Cancer Patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_27","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.coms.2015.06.004","article-title":"The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw","volume":"27","author":"Fantasia","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. N. Am."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-med-052218-020620","article-title":"New Frontiers in Osteoporosis Therapy","volume":"71","author":"Cheng","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-009-0962-6","article-title":"Fragility fractures of the hip and femur: Incidence and patient characteristics","volume":"21","author":"Nieves","year":"2010","journal-title":"Osteoporos. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1445-5994.2008.01824.x","article-title":"Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: An overview with recommendations for prevention and treatment","volume":"39","author":"Dickinson","year":"2009","journal-title":"Intern. Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"Loughnan","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation\u2014Lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1470-2045(18)30764-2","article-title":"Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma","volume":"20","author":"Mateos","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Udeshi","year":"2014","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: A systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/odi.13046","article-title":"Systemic comorbidities are associated with medication-related osteonecrosis of the jaws: Case\u2013control study","volume":"25","author":"McGowan","year":"2019","journal-title":"Oral Dis."},{"key":"ref_47","first-page":"1","article-title":"Oral health condition in cancer patients under bisphosphonate therapy","volume":"2021","author":"Caldas","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/scd.12318","article-title":"Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study","volume":"38","author":"Wazzan","year":"2018","journal-title":"Sp\u00e9c. Care Dent."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.joms.2009.04.051","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw: Clinical Features, Risk Factors, Management, and Treatment Outcomes of 26 Patients","volume":"67","author":"Sabino","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-Induced Exposed Bone (Osteonecrosis\/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_51","first-page":"E114","article-title":"Meaning and Limitation of Cortical Bone Width Measurement with DentaScan in Medication-Related Osteonecrosis of the Jaws","volume":"62","author":"Iwata","year":"2016","journal-title":"Kobe J. Med. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.coms.2015.06.005","article-title":"Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw","volume":"27","author":"Fung","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. N. Am."},{"key":"ref_53","unstructured":"Group OaDE (2019). Therapeutic Guidelines: Oral and Dental\u2014Version 3, Therapeutic Guidelines Limited. [3rd ed.]."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijom.2016.10.009","article-title":"Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: A systematic review","volume":"46","author":"Lemos","year":"2017","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.adaj.2017.04.002","article-title":"Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis","volume":"148","author":"Sgro","year":"2017","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/039463201002300224","article-title":"Clinical Experience with Spiramycin in Bisphosphonate-Associated Osteonecrosis of the Jaw","volume":"23","author":"Gasparini","year":"2010","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"31604","DOI":"10.1038\/srep31604","article-title":"The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection","volume":"6","author":"Russmueller","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jcms.2018.05.003","article-title":"Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up","volume":"46","author":"Nisi","year":"2018","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00198-019-05199-w","article-title":"A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: Daily versus weekly administration","volume":"31","author":"Ohbayashi","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial","volume":"38","author":"Sim","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_61","first-page":"1","article-title":"Serum Parathyroid Hormone Is a New Potential Risk Factor in Multiple Myeloma","volume":"2014","author":"Kang","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What Is the Role of Hyperbaric Oxygen in the Management of Bisphosphonate-Related Osteonecrosis of the Jaw: A Randomized Controlled Trial of Hyperbaric Oxygen as an Adjunct to Surgery and Antibiotics","volume":"70","author":"Freiberger","year":"2012","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sacco, R., Leeson, R., Nissan, J., Olate, S., De Castro, C.H.B.C., Acocella, A., and Lalli, A. (2019). A Systematic Review of Oxygen Therapy for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ). Appl. Sci., 9.","DOI":"10.3390\/app9051026"},{"key":"ref_64","first-page":"CD012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw (MRONJ)","volume":"10","author":"Mayer","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tenore, G., Zimbalatti, A., Rocchetti, F., Graniero, F., Gaglioti, D., Mohsen, A., Caputo, M., Lollobrigida, M., Lamazza, L., and De Biase, A. (2020). Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113505"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s10103-016-1929-4","article-title":"Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): A systematic review","volume":"31","author":"Weber","year":"2016","journal-title":"Lasers Med. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101651","DOI":"10.1016\/j.pdpdt.2020.101651","article-title":"Antimicrobial photodynamic and photobiomodulation adjuvant therapies for prevention and treatment of medication-related osteonecrosis of the jaws: Case series and long-term follow-up","volume":"29","author":"Tartaroti","year":"2020","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ijrobp.2010.03.029","article-title":"Complete Restoration of Refractory Mandibular Osteoradionecrosis by Prolonged Treatment with a Pentoxifylline-Tocopherol-Clodronate Combination (PENTOCLO): A Phase II Trial","volume":"80","author":"Delanian","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.oooo.2016.06.019","article-title":"Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: An observational retrospective study of initial case series","volume":"122","author":"Owosho","year":"2016","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: Pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.joms.2013.06.188","article-title":"Pentoxifylline and Tocopherol in the Treatment of Yearly Zoledronic Acid\u2013Related Osteonecrosis of the Jaw in a Corticosteroid-Induced Osteoporosis","volume":"72","author":"Magremanne","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcms.2020.09.008","article-title":"Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review","volume":"48","author":"Cavalcante","year":"2020","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","article-title":"A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs","volume":"3","author":"Crisan","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8768162","DOI":"10.1155\/2016\/8768162","article-title":"Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches","volume":"2016","author":"Lombard","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/scd.2012.0615","article-title":"Allogeneic Mesenchymal Stem Cell Therapy for Bisphosphonate-Related Jaw Osteonecrosis in Swine","volume":"22","author":"Li","year":"2013","journal-title":"Stem Cells Dev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:56:58Z","timestamp":1760165818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":76,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174479"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174479","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}